Critical issue is rapidity of review of new drugs

A. Rodger
DOI: https://doi.org/10.1136/bmj.a779
2008-07-14
British Medical Journal
Abstract:Baroness Finlay and Lord Crisp support copayments with four essential criteria.1 The fourth criterion will fail as the denominator is described as a small group in the scale of the NHS’s customer base. There is also the assurance that this is “mostly” for drugs yet to be reviewed by the National Institute for Health and Clinical Excellence (NICE). That is not the experience revealed by recent high profile cases in the …
What problem does this paper attempt to address?